On May 29, 2019 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, reported the Company will be presenting preliminary data from the ongoing Phase 1 dose-escalation trials of AB928, a potential best-in-class dual A2a/A2b receptor antagonist, in a poster session at the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place in Chicago, IL, from May 31-June 4, 2019 (Press release, Arcus Biosciences, MAY 29, 2019, View Source [SID1234536666]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentation details

Abstract Title: AB928, a Novel Dual Adenosine Antagonist, Combined With Chemotherapy or AB122 (anti-PD-1) in Patients With Advanced Tumors: Preliminary Results From Ongoing Phase 1 Studies
Abstract Number: 2604
Session Information: Developmental Immunotherapy and Tumor Immunobiology
Date and Time: Saturday, June 1, 8:00 a.m. – 11:00 a.m. Central Time
Location: Hall A

A copy of the poster will be available on the "Publications" section of the Arcus website at www.arcusbio.com.

Conference call details

Arcus will host a conference call and live webcast on Tuesday, June 25, 2019, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to provide a mid-year update on its clinical and preclinical programs. Investors interested in listening to the conference call may do so by dialing (866) 211-3164 in the U.S. or (647) 689-6573 internationally, using Conference ID: 7163128. In addition, the live webcast and accompanying slides will be available on the "Investors" section of the Arcus website at www.arcusbio.com. Following the live webcast, a replay will be available on the Company’s website for approximately 30 days.

About AB928

AB928 is an orally bioavailable, highly potent antagonist of the adenosine 2a and 2b receptors. The activation of these receptors by adenosine interferes with the activity of key populations of immune cells and inhibits an optimal anti-tumor immune response. By blocking these receptors, AB928 has the potential to reverse adenosine-induced immune suppression within the tumor microenvironment. AB928 was designed specifically for the oncology setting, with a profile that includes potent activity in the presence of high concentrations of adenosine and a minimal shift in potency due to non-specific protein binding, both essential properties for efficacy in the tumor microenvironment. AB928 has other attractive features, including high penetration of tumor tissue and low penetration through the healthy blood-brain barrier. In a Phase 1 trial in healthy volunteers, AB928 has been shown to be safe and well tolerated and to have pharmacokinetic and pharmacodynamic profiles consistent with a once-daily dosing regimen.

About AB122

AB122 is a fully human IgG4 antibody that potently and selectively blocks PD-1. The biochemical, biological and preclinical properties of AB122 have been shown to be similar to those of the marketed anti-PD-1 antibodies nivolumab and pembrolizumab. AB122 is being evaluated in ongoing Phase 1/1b dose-escalation and dose-expansion trials evaluating AB122 in combination with AB928, a potential best-in-class dual A2a/A2b receptor antagonist, and in combination with AB154, a potential best-in-class anti-TIGIT antibody. In May 2019, Arcus announced a clinical development collaboration with Strata Oncology utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate AB122 in a basket trial including tumor types that generally have low levels of response to anti-PD-1 therapy. AB122 is also being evaluated in an ongoing Phase 1 dose-escalation trial assessing monotherapy dosing schedules. The Company expects AB122 to form the backbone of many of its intra-portfolio combinations.

On May 29, 2019 Illumina, Inc. (NASDAQ:ILMN) reported that its executives will be speaking at the following investor conference and invited investors to participate via webcast (Press release, Illumina, MAY 29, 2019, View Source [SID1234536665]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, CA
Wednesday, June 12, 2019 at 10:00 am Pacific Time

The live webcast can be accessed in the Investor Relations section of Illumina’s web site under the "company" tab at www.illumina.com. A replay of the presentation will be posted on Illumina’s web site after the event and will be available for at least 30 days following.

On May 29, 2019 Exelixis, Inc. (Nasdaq: EXEL) reported that the company will be presenting at the following three investor conferences in June 2019 (Press release, Exelixis, MAY 29, 2019, View Source [SID1234536664]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 39th Annual Growth Stock Conference: Exelixis is scheduled to present at 5:00 PM EDT / 2:00 PM PDT on Wednesday, June 5, 2019 in Chicago.
Goldman Sachs 40th Annual Global Healthcare Conference: Exelixis is scheduled to present at 11:40 AM EDT / 8:40 AM PDT on Wednesday, June 12, 2019 in Rancho Palos Verdes, CA.
BMO Capital Markets Prescription for Success Healthcare Conference: Exelixis is scheduled to present at 8:00 AM EDT / 5:00 AM PDT on Tuesday, June 25, 2019 in New York.
To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to each presentation to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for 14 days following each presentation.

On May 29, 2019 Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, reported that it will be presenting preclinical data for its Cargocyte technology platform program targeting difficult to treat Breast Cancer at the BIO International Convention meeting June 3-6 in Philadelphia, PA (Press release, Cytonus Therapeutics, MAY 29, 2019, View Source [SID1234536663]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses.

"We are honored to have been selected to present Cytonus’ first-of-its-kind Cargocyte technology platform at this year’s BIO convention and look forward to sharing our promising CA-IL12 data in treating Triple Negative Breast Cancer in preclinical animal models," said Remo Moomiaie-Qajar, M.D., president and CEO of Cytonus.

Details of the presentation:

Company Name: Cytonus Therapeutics, Inc.
Presentation Date: Thursday, June 6
Presentation Time: 1:30:00 PM
Presentation Room: Theater 1
Speaker: Remo Moomiaie-Qajar, M.D., CEO

On May 29, 2019 A first-ever inhibitor of a cancer gene found in some lung, colorectal and other cancers and the effectiveness of chimeric antigen receptor (CAR) T cell therapy for patients with chronic lymphocytic leukemia are just some of the research topics that City of Hope physicians and scientists reported that it will present at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2019 annual meeting May 31 – June 4 in Chicago’s McCormick Place (Press release, City of Hope, MAY 29, 2019, View Source [SID1234536662]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

More than 38,000 oncology professionals and others will attend the conference to learn about the latest scientific research on cancer treatment, detection and prevention.

"ASCO brings together doctors, nurses and other medical professionals with the important goal of discussing and sharing the latest cancer research and treatment," said Michael Caligiuri, M.D., president of City of Hope National Medical Center and Deana and Steve Campbell Physician-in-Chief Distinguished Chair. "The annual meeting contributes to City of Hope’s deep commitment to developing and implementing the most effective and innovative therapies. City of Hope patients ultimately benefit from the knowledge shared at ASCO (Free ASCO Whitepaper)."

City of Hope doctors and scientists will present oral and poster presentations on a wide array of topics. They include:

First clinical trial testing KRAS G12C inhibitor in lung, colorectal and other cancers

Abstract No: 3003

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Monday, June 3, 8-11 a.m.

McCormick Place, S406

Marwan Fakih, M.D., professor of City of Hope’s Department of Medical Oncology & Therapeutics Research and medical director of Judy & Bernard Briskin Center for Clinical Research, will present a study on the first in-human trial targeting the KRAS G12C oncogene (a gene that when mutated drives tumor growth), which is found in up to 15% of lung cancer patients and 3% of colorectal cancer patients. City of Hope is one of the leading centers evaluating AMG 510, a targeted therapy that, when taken orally on a daily basis, inhibits the growth of KRAS G12C tumors.

The study examined the safety and efficacy of AMG 510 in 20 patients who continue to take the therapy. Most of the patients had advanced cancer and had taken three or more prior lines of treatment; the majority also had colorectal cancer.

Initial results show that two patients with nonsmall cell lung cancer (NSCLC) had partial remissions and six patients (two with NSCLC and four with colorectal cancer) had cancer that had stop growing.

Results so far have demonstrated that the disease is safe for use in patients and very well-tolerated with minimal side effects.

"This is the first-ever KRAS inhibitor that shows anti-tumor activity," Fakih said. "That is quite significant and depending on future results, it has the potential to be life-changing for patients with KRAS G12C."

Fakih will discuss updated clinical results during his ASCO (Free ASCO Whitepaper) presentation.

CAR T therapy for chronic lymphocytic lymphoma

Abstract No: 7501

TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Tuesday, June 4, 9:45 a.m. – 12:45 p.m.

McCormick Place, E451

Tanya Siddiqi, M.D., associate clinical professor of hematology and director of the chronic lymphocytic lymphoma program within City of Hope’s Toni Stephenson Lymphoma Center, will present an oral abstract on a CAR T cell therapy for chronic lymphocytic leukemia (CLL). Lisocabtagene maraleucel, also known as liso-cel and JCAR017, targets CD19-positive cancer cells. There is not a lot of current data on CAR T cell therapies for CLL, which is an incurable but slow, growing chronic cancer.

"At some point, CLL can become more aggressive and resistant to even the new targeted therapies," Siddiqi said. "Therefore, novel therapeutics are needed, especially for patients with high risk disease (having markers like deletion 17p, complex cytogenetics, unmutated IGVH) or those who have not responded to other therapies."

The phase 1 study had 15 evaluable patients who had all received prior therapies, including ibrutinib (a multikinase inhibitor), and whose cancer had returned. Initial data shows that there was no minimal residual disease, or traces of cancer, in about 70% of patients as early as 30 days after receiving the CAR T cells. Seven patients also achieved complete remission. The overall response rate (patients who showed a response to the therapy) at six months was 83%.

Patients also had manageable toxicities, or side effects caused by the treatment; these included low grade cytokine release syndrome and neurotoxicity.

"Our study brings additional information showing that the product is efficacious with manageable toxicities in patients who have progressed after ibrutinib," Siddiqi said.

Siddiqi will also present updated study results at the ASCO (Free ASCO Whitepaper) presentation.

In addition, City of Hope doctors will also speak at plenary and education sessions. They include: Saro Armenian, D.O., M.P.H., a City of Hope pediatric hematologist/oncologist, will discuss pediatric oncology abstracts on Sunday, June 2; Tanya Dorff, M.D., associate clinical professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, will discuss prostate cancer abstracts on Sunday, June 2, and will also speak at an education session on diagnostics and therapeutics for prostate cancer on Friday, May 31; Karen Reckamp, M.D., M.S., co-director of City of Hope’s Lung Cancer and Thoracic Oncology Program, will discuss lung cancer abstracts on Monday, June 3; Alex Herrera, M.D., assistant professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation, will discuss relapsed Hodgkin lymphoma at an education session on Monday, June 3; Kim Margolin, M.D., clinical professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, will discuss immunotherapy for brain metastases at an education session on Tuesday, June 4; and Jasmine Zain, M.D., director of City of Hope’s T cell Lymphoma Program, will discuss non-Hodgkin lymphoma abstracts on Tuesday, June 4.